DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Amyotrophic Lateral Sclerosis
  4. Research Highlights/News
  5. 2017 Amyotrophic Lateral Sclerosis Research Program

Amyotrophic Lateral Sclerosis

NEWS RELEASE

Released: January 23, 2017

Defense Health Program
Department of Defense Amyotrophic Lateral Sclerosis Research Program
Funding Opportunities for Fiscal Year 2017 (FY17)

Due to the current Continuing Resolution, the Fiscal Year 2017 (FY17) Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP), the ALSRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

FY17 ALSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these program announcements is contingent on the availability of Federal funds appropriated for the ALSRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Award Mechanisms: The following mechanisms are planned for release:

Award Mechanism Eligibility Key Mechanism Elements Funding
Therapeutic Development Award Independent investigators at all academic levels
  • Pre-application is required; full application submission is by invitation only
  • Supports post-discovery, preclinical development of therapeutics for ALS
  • Preliminary data, including identify and purity of an identified bioactive compound(s), are required
  • Types of efforts that will be supported include:
    • Validation of lead pharmacological agents up to IND submission
    • Optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices
  • Collaboration with industry is encouraged
  • Clinical trials are not allowed
  • Does not support screening or development of screens or models
  • Maximum funding of $1,000,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 2 years
Therapeutic Idea Award Independent investigators at all academic levels
  • Pre-application is required; full application submission is by invitation only.
  • Supports hypothesis-driven drug discovery efforts focused on ALS therapeutics
  • Preliminary data are not required
  • Types of efforts that will be supported include:
    • Novel exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality
    • Development, validation and use of novel high-throughput screens and model systems based on novel targets or innovative drug systems
    • Development of methods for measuring engagement of mechanistic targets by drug candidates
  • Innovation in technologies and techniques is an important criteria for application evaluation
  • Characterization of mechanisms for the purpose of identifying new targets is outside of the scope of this announcement
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 2 years

Submission deadlines are not available until the Program Announcements are released. A pre-application is required and must be submitted through the CDMRP electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.

Full applications must be submitted through the federal government's single-entry portal, Grants.gov. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from Grants.gov. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org. For more information about the ALSRP or other CDMRP administered programs, please visit the CDMRP website (httpcdmrp.health.mil.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Monday, December 16, 2024